Sarah Gill

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study”.

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Journal of Clinical Oncology(2024)10.1200/jco.23.02076

N/A

0.644DataRank · unranked

20 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5501

N/A

0DataRank · unranked

9 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial

International Journal of Gynecological Cancer(2023)10.1136/ijgc-2023-esgo.13

N/A

0DataRank · unranked

2 citations

Line Bjørge, Robert L. Coleman, Oleksandr Zub, Eirwen M. Miller, Roberto Angioli +15 more

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5525

N/A

0DataRank · unranked

1 citations

Andrew B. Nixon, Danielle Enserro, David Bender, B.J. Rimel, Matthew A. Powell +12 more

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5629

N/A

0DataRank · unranked

1 citations

David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +10 more

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma

Journal of Experimental & Clinical Cancer Research(2025)10.1186/s13046-025-03406-7

N/A

0DataRank · unranked

1 citations

Valentina Zanfagnin, Conway Xu, Erik Jessen, Yuanhang Liu, Chen Wang +17 more